Published in Proc Natl Acad Sci U S A on October 16, 2001
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
Unconventional recognition of peptides by T cells and the implications for autoimmunity. Nat Rev Immunol (2012) 1.29
HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. Nat Struct Mol Biol (2012) 1.25
Conformational lability in the class II MHC 310 helix and adjacent extended strand dictate HLA-DM susceptibility and peptide exchange. Proc Natl Acad Sci U S A (2011) 1.23
Identification of the lateral interaction surfaces of human histocompatibility leukocyte antigen (HLA)-DM with HLA-DR1 by formation of tethered complexes that present enhanced HLA-DM catalysis. J Exp Med (2002) 1.23
The impact of DM on MHC class II-restricted antigen presentation can be altered by manipulation of MHC-peptide kinetic stability. J Exp Med (2006) 1.18
Model for the peptide-free conformation of class II MHC proteins. PLoS One (2008) 1.17
Empty class II major histocompatibility complex created by peptide photolysis establishes the role of DM in peptide association. J Biol Chem (2007) 1.16
The utility and limitations of current Web-available algorithms to predict peptides recognized by CD4 T cells in response to pathogen infection. J Immunol (2012) 1.13
Small molecules that enhance the catalytic efficiency of HLA-DM. J Immunol (2006) 1.10
Cutting edge: HLA-DM functions through a mechanism that does not require specific conserved hydrogen bonds in class II MHC-peptide complexes. J Immunol (2009) 1.10
Conformational variation in structures of classical and non-classical MHCII proteins and functional implications. Immunol Rev (2012) 1.00
The convergent roles of tapasin and HLA-DM in antigen presentation. Trends Immunol (2008) 0.99
HLA-DM mediates epitope selection by a "compare-exchange" mechanism when a potential peptide pool is available. PLoS One (2008) 0.97
Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection. Immunol Res (2010) 0.90
HLA-DM mediates peptide exchange by interacting transiently and repeatedly with HLA-DR1. Mol Immunol (2009) 0.88
The control of the specificity of CD4 T cell responses: thresholds, breakpoints, and ceilings. Front Immunol (2013) 0.87
An MHC class II restriction bias in CD4 T cell responses toward I-A is altered to I-E in DM-deficient mice. J Immunol (2008) 0.82
Evaluating the Role of HLA-DM in MHC Class II-Peptide Association Reactions. J Immunol (2015) 0.81
The melting pot of the MHC II peptidome. Curr Opin Immunol (2016) 0.80
A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination. J Immunol Methods (2014) 0.79
Resolving multiple protein-peptide binding events: implication for HLA-DQ2 mediated antigen presentation in celiac disease. Chem Asian J (2012) 0.79
Measurement of Peptide Binding to MHC Class II Molecules by Fluorescence Polarization. Curr Protoc Immunol (2014) 0.78
The Thermodynamic Mechanism of Peptide-MHC Class II Complex Formation Is a Determinant of Susceptibility to HLA-DM. J Immunol (2015) 0.77
A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells. F1000Res (2016) 0.76
Structural Insights Into HLA-DM Mediated MHC II Peptide Exchange. Curr Top Biochem Res (2011) 0.76
MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell (1994) 6.92
Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature (1995) 3.40
Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol (1997) 3.24
The human class II MHC protein HLA-DR1 assembles as empty alpha beta heterodimers in the absence of antigenic peptide. Cell (1992) 2.79
Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science (1996) 2.68
HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature (1992) 2.54
Interaction between a "processed" ovalbumin peptide and Ia molecules. Proc Natl Acad Sci U S A (1986) 2.42
An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature (1994) 2.41
Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc Natl Acad Sci U S A (1991) 2.25
A kinetic intermediate in the reaction of an antigenic peptide and I-Ek. Nature (1989) 1.89
High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. J Immunol (1990) 1.85
HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature (1994) 1.80
HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med (1996) 1.77
Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J (1996) 1.74
Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science (1992) 1.63
Formation of a highly peptide-receptive state of class II MHC. Immunity (1998) 1.58
HLA-DM recognizes the flexible conformation of major histocompatibility complex class II. J Exp Med (2000) 1.56
Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity (2000) 1.54
The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity (1998) 1.53
MHC class II function preserved by low-affinity peptide interactions preceding stable binding. Nature (1994) 1.50
Empty and peptide-loaded class II major histocompatibility complex proteins produced by expression in Escherichia coli and folding in vitro. Protein Expr Purif (1999) 1.50
HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity (1997) 1.45
Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1. J Biol Chem (2000) 1.41
Crystal structure of mouse H2-M. Immunity (1998) 1.34
Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. J Immunol (1999) 1.26
A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding. Biochemistry (1999) 1.21
Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci U S A (1996) 1.20
Kinetics of peptide binding to the class II MHC protein I-Ek. Biochemistry (2000) 1.14
A three-step kinetic mechanism for peptide binding to MHC class II proteins. Biochemistry (2000) 1.11
Conformational isomers of a class II MHC-peptide complex in solution. J Mol Biol (1999) 1.10
Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM. J Biol Chem (1998) 1.06
Ovalbumin(323-339) peptide binds to the major histocompatibility complex class II I-A(d) protein using two functionally distinct registers. Biochemistry (1999) 1.06
Kinetic intermediates in the reactions between peptides and proteins of major histocompatibility complex class II. Proc Natl Acad Sci U S A (1994) 1.02
How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol Today (1997) 1.02
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59
Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature (1993) 8.75
Vibrational spectroscopy of bacteriorhodopsin mutants: light-driven proton transport involves protonation changes of aspartic acid residues 85, 96, and 212. Biochemistry (1988) 4.93
Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature (1992) 3.85
Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature (1994) 3.60
Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg (1993) 3.45
Aspartic acid substitutions affect proton translocation by bacteriorhodopsin. Proc Natl Acad Sci U S A (1988) 3.13
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol (2001) 2.91
Substitution of amino acids Asp-85, Asp-212, and Arg-82 in bacteriorhodopsin affects the proton release phase of the pump and the pK of the Schiff base. Proc Natl Acad Sci U S A (1990) 2.80
Phosphorylation of T cell receptor zeta is regulated by a lipid dependent folding transition. Nat Struct Biol (2000) 2.67
Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J (1990) 2.42
Complications and side effects of hyperbaric oxygen therapy. Aviat Space Environ Med (2000) 2.17
Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer (1993) 2.01
Developmental plasticity of CNS microglia. Proc Natl Acad Sci U S A (2001) 1.95
The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Immunity (2000) 1.88
Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro. Nature (1994) 1.79
Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg (1994) 1.75
Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br J Surg (1996) 1.69
Shared decision making for in-patients with schizophrenia. Acta Psychiatr Scand (2006) 1.63
Vibrational spectroscopy of bacteriorhodopsin mutants: I. Tyrosine-185 protonates and deprotonates during the photocycle. Proteins (1988) 1.63
Social phobia in spasmodic torticollis. J Neurol Neurosurg Psychiatry (2001) 1.62
Stented versus nonstented pancreaticojejunostomy after pancreatoduodenectomy: a prospective study. Ann Surg (1999) 1.60
Bacteriorhodopsin mutants containing single tyrosine to phenylalanine substitutions are all active in proton translocation. Proc Natl Acad Sci U S A (1987) 1.58
Formation of a highly peptide-receptive state of class II MHC. Immunity (1998) 1.58
Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity (2000) 1.54
Structure-function studies on bacteriorhodopsin. V. Effects of amino acid substitutions in the putative helix F. J Biol Chem (1987) 1.51
MHC class II function preserved by low-affinity peptide interactions preceding stable binding. Nature (1994) 1.50
Empty and peptide-loaded class II major histocompatibility complex proteins produced by expression in Escherichia coli and folding in vitro. Protein Expr Purif (1999) 1.50
[Comparison of the quality of life after subtotal and total gastrectomy for stomach carcinoma]. Dtsch Med Wochenschr (1996) 1.50
Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer (1998) 1.49
Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc Natl Acad Sci U S A (1996) 1.42
Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1. J Biol Chem (2000) 1.41
Extracellular antigen processing and presentation by immature dendritic cells. Proc Natl Acad Sci U S A (1999) 1.41
Optimized differential diagnosis of breast lesions by combined B-mode and color Doppler sonography. Ultrasound Obstet Gynecol (1997) 1.41
Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys (2001) 1.38
Unilateral blepharochalasis. Arch Dermatol (1979) 1.31
Structure-function studies on bacteriorhodopsin. IV. Purification and renaturation of bacterio-opsin polypeptide expressed in Escherichia coli. J Biol Chem (1987) 1.31
Intermediates in the folding of the membrane protein bacteriorhodopsin. Nat Struct Biol (1995) 1.28
Cutting edge: detection of antigen-specific CD4+ T cells by HLA-DR1 oligomers is dependent on the T cell activation state. J Immunol (2001) 1.27
Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc Natl Acad Sci U S A (1999) 1.26
The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding. Structure (1997) 1.26
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood (1999) 1.25
Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. J Immunol (1999) 1.21
Conserved amino acids in F-helix of bacteriorhodopsin form part of a retinal binding pocket. FEBS Lett (1989) 1.21
A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding. Biochemistry (1999) 1.21
Lymphocyte activation provokes modification of a lymphocyte-specific protein tyrosine kinase (p56lck). J Immunol (1989) 1.19
Structural analysis of a peptide--HLA class II complex: identification of critical interactions for its formation and recognition by T cell receptor. Int Immunol (1989) 1.18
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia (2009) 1.16
Influence of Epstein-Barr virus genomes on patient survival in Hodgkin's disease. Am J Clin Pathol (1992) 1.16
Diagnosis of acute myocardial infarction in the emergency room: a prospective assessment of clinical decision making and the usefulness of immediate cardiac enzyme determination. J Community Health (1979) 1.15
Accessory molecules for MHC class II peptide loading. Curr Opin Immunol (2000) 1.14
Prognostic factors in gastric stump carcinoma. Ann Surg (2000) 1.14
Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia (2012) 1.13
Prediction of flap necrosis with laser induced indocyanine green fluorescence in a rat model. Br J Plast Surg (2005) 1.13
A three-step kinetic mechanism for peptide binding to MHC class II proteins. Biochemistry (2000) 1.11
Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma (1996) 1.10
Receptor clustering and transmembrane signaling in T cells. Trends Biochem Sci (2001) 1.06
Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol (2004) 1.06
Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM. J Biol Chem (1998) 1.06
Self-release of CLIP in peptide loading of HLA-DR molecules. Science (1995) 1.05
Structure-function studies on bacteriorhodopsin. VIII. Substitutions of the membrane-embedded prolines 50, 91, and 186: the effects are determined by the substituting amino acids. J Biol Chem (1989) 1.05
Receptor proximity, not intermolecular orientation, is critical for triggering T-cell activation. J Biol Chem (2001) 1.05
The folding and structural integrity of the first LIN-12 module of human Notch1 are calcium-dependent. Biochemistry (1999) 1.04
Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer (2001) 1.03
Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg (1995) 1.00
Comparison of visual inspection and Papanicolau (PAP) smears for cervical cancer screening in Honduras: should PAP smears be abandoned? Trop Med Int Health (2007) 0.99
[Risk of surgical therapy of stomach cancer in Germany. Results of the German 1992 Stomach Cancer Study. German Stomach Cancer Study Group ('92)]. Chirurg (1994) 0.98
Is perceived social support a predictor of survival for patients undergoing autologous peripheral blood stem cell transplantation? Psychooncology (2005) 0.98
Management of 219 consecutive cases of postcatheterization pseudoaneurysm. J Am Coll Cardiol (1997) 0.98
Problem of proximal third gastric carcinoma. World J Surg (1995) 0.97
Vibrational spectroscopy of bacteriorhodopsin mutants: chromophore isomerization perturbs tryptophan-86. Biochemistry (1989) 0.96
Correlation of symptoms and results of direct bacterial localization in patients with urinary tract infections. J Urol (1984) 0.96
Structure and thermal stability of monomeric bacteriorhodopsin in mixed phospholipid/detergent micelles. Proteins (1989) 0.95
Effects of amino acid substitutions in the F helix of bacteriorhodopsin. Low temperature ultraviolet/visible difference spectroscopy. J Biol Chem (1988) 0.95
Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles. J Immunol (2001) 0.95
Developing and shedding inhibitions: how MHC class II molecules reach maturity. Curr Opin Immunol (1996) 0.95
Paternal age is a risk factor for Alzheimer disease in the absence of a major gene. Neurogenetics (1998) 0.95
Comparison of x-ray crystal structures of an acyl-enzyme intermediate of subtilisin Carlsberg formed in anhydrous acetonitrile and in water. Proc Natl Acad Sci U S A (1998) 0.95
T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model. Biophys J (2001) 0.94
Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. Eur J Nucl Med Mol Imaging (2006) 0.94
[Prognostic factors in stomach cancer. Results of a uni- and multivariate analysis]. Chirurg (1992) 0.94
Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization. J Immunol (1998) 0.93
A planning comparison of dynamic IMRT for different collimator leaf thicknesses with helical tomotherapy and RapidArc for prostate and head and neck tumors. Strahlenther Onkol (2010) 0.93
Oxidation of methionine residues affects the structure and stability of apolipoprotein A-I in reconstituted high density lipoprotein particles. Chem Phys Lipids (2001) 0.92
Epitope-specific enhancement of antigen presentation by invariant chain. J Exp Med (1993) 0.92
Prognostic factors in resected primary small bowel tumors. Dig Surg (1998) 0.91
Autoantigenic HCgp39 epitopes are presented by the HLA-DM-dependent presentation pathway in human B cells. J Immunol (2001) 0.90
Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR. J Immunol (1995) 0.90
New aspects of prognostic factors in adenocarcinomas of the small bowel. Hepatogastroenterology (2001) 0.90
Substitution of amino acids in helix F of bacteriorhodopsin: effects on the photochemical cycle. Biochemistry (1989) 0.88
The crystal structure of subtilisin Carlsberg in anhydrous dioxane and its comparison with those in water and acetonitrile. Proc Natl Acad Sci U S A (1997) 0.87
A diverse set of oligomeric class II MHC-peptide complexes for probing T-cell receptor interactions. Chem Biol (2000) 0.87
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol (2001) 0.87
Overexpression of human nucleolar proteins in insect cells: characterization of nucleolar protein p120. Protein Expr Purif (1996) 0.86
Immunocytochemical localization of nucleophosmin and RH-II/Gu protein in nucleoli of HeLa cells after treatment with actinomycin D. Acta Histochem (2001) 0.86
Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol (1993) 0.86